Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel Free HALO Stock Alerts

HaloSource (HALO) Competitors

HaloSource logo
Compare

HALO vs. PXS, MXC, RGT, CEL, and IDP

Should you buy HaloSource stock or one of its competitors? HaloSource's main competitors and comparable companies include Provexis (PXS), Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), and InnovaDerma (IDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HaloSource compare to Provexis?

HaloSource (LON:HALO) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

HaloSource has a net margin of 0.00% compared to Provexis' net margin of -69.30%. HaloSource's return on equity of 0.00% beat Provexis' return on equity.

Company Net Margins Return on Equity Return on Assets
HaloSourceN/A N/A N/A
Provexis -69.30%-49.45%-56.14%

In the previous week, HaloSource's average media sentiment score of 0.00 equaled Provexis'average media sentiment score.

Company Overall Sentiment
HaloSource Neutral
Provexis Neutral

HaloSource has higher earnings, but lower revenue than Provexis. Provexis is trading at a lower price-to-earnings ratio than HaloSource, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HaloSourceN/AN/AN/A-£3.72N/A
Provexis£871.27K24.99-£619.15K-£0.02N/A

7.9% of Provexis shares are held by institutional investors. 11.8% of Provexis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

HaloSource and Provexis tied by winning 4 of the 8 factors compared between the two stocks.

How does HaloSource compare to Argent BioPharma?

Argent BioPharma (LON:MXC) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

1.2% of Argent BioPharma shares are owned by institutional investors. 8.2% of Argent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, HaloSource's average media sentiment score of 0.00 beat Argent BioPharma's score of -0.54 indicating that HaloSource is being referred to more favorably in the news media.

Company Overall Sentiment
Argent BioPharma Negative
HaloSource Neutral

HaloSource has lower revenue, but higher earnings than Argent BioPharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argent BioPharma£1.32M0.00-£17.02M-£1.66N/A
HaloSourceN/AN/AN/A-£3.72N/A

Company Net Margins Return on Equity Return on Assets
Argent BioPharmaN/A N/A -58.96%
HaloSource N/A N/A N/A

Summary

Argent BioPharma beats HaloSource on 4 of the 7 factors compared between the two stocks.

How does HaloSource compare to Argent BioPharma?

Argent BioPharma (LON:RGT) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

1.1% of Argent BioPharma shares are owned by institutional investors. 17.8% of Argent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

HaloSource has a net margin of 0.00% compared to Argent BioPharma's net margin of -1,967.38%. Argent BioPharma's return on equity of 279.26% beat HaloSource's return on equity.

Company Net Margins Return on Equity Return on Assets
Argent BioPharma-1,967.38% 279.26% -108.57%
HaloSource N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argent BioPharmaN/AN/A-£17.53M-£0.24N/A
HaloSourceN/AN/AN/A-£3.72N/A

In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company Overall Sentiment
Argent BioPharma Neutral
HaloSource Neutral

Summary

Argent BioPharma beats HaloSource on 5 of the 7 factors compared between the two stocks.

How does HaloSource compare to Celadon Pharmaceuticals?

HaloSource (LON:HALO) and Celadon Pharmaceuticals (LON:CEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

10.7% of Celadon Pharmaceuticals shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

HaloSource has higher earnings, but lower revenue than Celadon Pharmaceuticals. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than HaloSource, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HaloSourceN/AN/AN/A-£3.72N/A
Celadon Pharmaceuticals£123.38K66.61-£4.97M-£7.98N/A

HaloSource has a net margin of 0.00% compared to Celadon Pharmaceuticals' net margin of -9,520.00%. HaloSource's return on equity of 0.00% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
HaloSourceN/A N/A N/A
Celadon Pharmaceuticals -9,520.00%-131.82%-34.40%

In the previous week, HaloSource's average media sentiment score of 0.00 equaled Celadon Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
HaloSource Neutral
Celadon Pharmaceuticals Neutral

Summary

HaloSource and Celadon Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does HaloSource compare to InnovaDerma?

HaloSource (LON:HALO) and InnovaDerma (LON:IDP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Company Net Margins Return on Equity Return on Assets
HaloSourceN/A N/A N/A
InnovaDerma N/A N/A N/A

In the previous week, HaloSource's average media sentiment score of 0.00 equaled InnovaDerma'saverage media sentiment score.

Company Overall Sentiment
HaloSource Neutral
InnovaDerma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HaloSourceN/AN/AN/A-£3.72N/A
InnovaDerma£9.82M0.00N/A-£7.50N/A

Summary

HaloSource beats InnovaDerma on 2 of the 3 factors compared between the two stocks.

Get HaloSource News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HALO vs. The Competition

Export
MetricHaloSourcePharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£10.80M£12.46B£7.16B£2.87B
Dividend YieldN/A2.62%2.56%6.23%
P/E Ratio-2.62799.74274.10366.83
Price / SalesN/A763.35656.0083,599.70
Price / CashN/A89.2577.0427.89
Price / BookN/A10.3910.336.33
Net IncomeN/A£2.85B£3.50B£5.89B
7 Day Performance-1.71%-3.70%-3.35%-0.69%
1 Month Performance4.90%0.78%-0.43%0.18%
1 Year PerformanceN/A3.48%19.21%20.03%

HaloSource Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
HaloSource
N/AN/AN/AN/A£10.80MN/AN/A390
PXS
Provexis
N/AGBX 1.02
-2.9%		N/A+42.8%£23.93M£871.27KN/A4
MXC
Argent BioPharma
N/AN/AN/AN/A£9.65M£1.32MN/A5
RGT
Argent BioPharma
N/AN/AN/AN/A£8.31MN/AN/AN/A
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat		N/AN/A£8.22M£123.38KN/A2,780

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HALO) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
My ‘one day’ retirement secret
TradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...
TradeSmith | Sponsoredtc pixel